Kalon Biotherapeutics is a private company formed by The Texas AM University System in Spring 2011. It was formed to provide advanced biologics development manufacturing in the newly constructed National Center for Therapeutics Manufacturing (NCTM) building, a state-of-the-art cGMP facility. Kalon enables rapid, cost-effective drug development through a flexible and scalable clinical manufacturing platform with capabilities to support all classes of biological drug products including vaccines, monoclonal antibodies, cellular and gene therapies. Their capabilities include full upstream and downstream processing assets, supporting both microbial and mammalian expression systems. They can scale up to a 2,000 L batch size for clinical materials manufacture supporting up to Phase III run in. Kalon is a key partner of Research Valley’s One Health Plus Biocorridor One-Stop-Shop Biotech Infrastructure Pipeline, to discover new therapies in plant, animal, and human health, perform preclinical evaluations, and utilize flexible, scalable Biotech Infrastructure Pipeline biopharmaceutical manufacturing, all in one convenient location.